Last Updated : February 29, 2024
1. About Provisional Funding Algorithms
The provisional algorithm process is used to provide advice to drug programs when they have indicated that there is need to establish an appropriate place in therapy for new oncology drugs relative to alternative treatments that are currently reimbursed by the drug programs. The process ascertains the impact of new therapies on the sequencing of treatments for the purposes of reimbursement (e.g., should reimbursing a new drug result in a shift or a displacement of other available treatments). While broad in scope, funding algorithms are focused on reimbursement decision-making; they are not treatment algorithms or guidelines and do not fully detail the clinical management of cancer patients.
CADTH will initiate the development of a provisional algorithm in the following instances:
Please review the Procedures for CADTH Reimbursement Reviews for complete details.
CADTH issues a call for stakeholder input at the time the provisional algorithm project is initiated and seeks stakeholder feedback on the draft provisional algorithm. The following stakeholders are eligible to contribute: patient groups, clinician groups, the participating drug programs, and drug manufacturers whose products may be directly impacted by the provisional algorithm.
Open calls for input and feedback are highlighted in the CADTH Weekly Update and instructions for contributing are provided below.
To provide initial input at the outset of the provisional algorithm project:
To provide stakeholder feedback on a draft provisional algorithm report:
Updates on CADTH provisional funding algorithms are posted to this page. Reports are searchable and freely available to anyone to use, download, or print for non-commercial and personal use, or private research and study, provided you do not modify them, and appropriate credit is given to CADTH.
Tumour Type |
Therapeutic Area |
Project Number |
Project Status |
Date Final Report Posted |
---|---|---|---|---|
Breast | HER2-positive metastatic breast cancer | PH0006-000 | Complete | April 12, 2022 |
Breast | HER2-positive metastatic breast cancer | PH0016-000 | Complete | January 13, 2023 |
Breast | HR+ HER2- Breast Cancer | PH0018-000 | Complete | March 8, 2023 |
Breast | HR positive, HER2 negative breast cancer | PH0041-000 | Open for Stakeholder Feedback | |
Breast | HR+ HER2- Breast Cancer and Triple Negative Breast Cancer, with inclusion of HER2 Low Breast Cancer | PH0033-000 | Complete | December 7, 2023 |
Breast | Triple Negative Breast Cancer | PH0024-000 | Complete | June 14, 2023 |
Gastrointestinal | Colorectal cancer | PH0043-000 | Pending | |
Gastrointestinal | Unresectable Hepatocellular Carcinoma | PH0003-000 | Complete | April 21, 2021 |
Gastrointestinal | Unresectable Hepatocellular Carcinoma | PH0036-000 | Complete | January 24, 2024 |
Gastrointestinal | Human Epidermal Growth Factor Receptor 2(HER2) Negative Gastric, Gastroesophageal Junction (GEJ), or Esophageal Cancer | PH0010-000 | Complete | June 21, 2022 |
Gastrointestinal | Colon Cancer | PH0005-000 | Complete | November 12, 2021 |
Genitourinary | Metastatic Urothelial Carcinoma | PH0008-000 | Complete | March 28, 2022 |
Genitourinary | Metastatic Urothelial Carcinoma | PH0017-000 | Complete | January 11, 2023 |
Genitourinary | Renal Cell Carcinoma | PH0013-000 | Complete | September 6, 2022 |
Genitourinary | Renal Cell Carcinoma | PH0019-000 | Complete | January 11, 2023 |
Genitourinary | Renal Cell Carcinoma | PH0037-000 | Complete | February 21, 2024 |
Genitourinary | Prostate cancer | PH0023-000 | Complete | May 3, 2023 |
Genitourinary | Prostate Cancer | PH0034-000 | Complete | October 27, 2023 |
Genitourinary | Prostate cancer | PH0039-000 | Open for Stakeholder Feedback | |
Leukemia | Adult B-cell precursor Acute Lymphoblastic Leukemia, Philadelphia chromosome negative | PH0002-000 | Complete | February 24, 2021 |
Leukemia | Adult B-Cell Precursor Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative and Positive | PH0030-000 | Complete | June 28, 2023 |
Leukemia | Chronic Lymphocytic Leukemia | PH0004-000 | Complete | May 18, 2021 |
Leukemia | Chronic Lymphocytic Leukemia | PH0035-000 | Complete | October 27, 2023 |
Leukemia | Chronic Lymphocytic Leukemia | PH0038-000 | Active | |
Lung | Anaplastic Lymphoma Kinase Positive Non-small Cell Lung Cancer | PH0009-000 | Complete | May 24, 2022 |
Lung | NSCLC without actionable oncogenic alterations | PH0012-000 | Complete | August 5, 2022 |
Lung | NSCLC without actionable oncogenic alterations | PH0015-000 | Complete | December 1, 2022 |
Lung | RET-fusion positive NSCLC | PH0020-000 | Withdrawn | - |
Lung | RET fusion-positive non-small cell lung cancer | PH0026-000 | Complete | June 1, 2023 |
Lung | Non-Small Cell Lung Cancer (NSCLC) with Activating Epidermal Growth Factor Receptor (EGFR) Mutations | PH0028-000 | Complete | June 1, 2023 |
Lung | Non-Small Cell Lung Cancer without actionable oncogenic alterations | PH0029-000 | Complete | August 10, 2023 |
Lymphoma | Adult Classical Hodgkin Lymphoma | PH0007-000 | Complete | February 2, 2022 |
Lymphoma | Large B-Cell Lymphoma | PH0027-000 | Complete | April 11, 2023 |
Lymphoma | Large B-Cell Lymphoma | PH0040-000 | Open for Stakeholder Feedback | |
Myeloma | Multiple Myeloma | PH0011-000 | Complete | May 25, 2022 |
Myeloma | Multiple Myeloma | PH0014-000 | Complete | November 15, 2022 |
Myeloma | Multiple Myeloma | PH0031-000 | Complete | July 27, 2023 |
Other | Differentiated Thyroid Carcinoma | PH0021-000 | Complete | February 06, 2023 |
Skin & Melanoma | Melanoma | PH0022-000 | Complete | February 06, 2023 |
Skin & Melanoma | Cutaneous Melanoma | PH0042-000 | Open for Stakeholder Input |